Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorImperial College London

About this trial

Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all. Jaundice, weight loss and pain are 'red flag' symptoms of pancreatic cancer that are linked to incurable disease. At the moment only patients with 'red flag' symptoms are urgently referred for diagnostic testing to find out if they have the cancer. As a result, late diagnosis is a common feature of pancreatic cancer. This leads to limited treatment options being available to patients by the time they are diagnosed, and ultimately results in poor survival rates.

There is a clear need to improve earlier detection of pancreatic cancer so that patients with pancreatic cancer can be identified earlier and faster, enabling them to start treatment more quickly.

The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that may be altered by pancreatic cancers. For patients with non-specific symptoms, this test would help general practitioners (GPs) to identify those patients that may indeed have an underlying pancreatic cancer, who would benefit from referral for specialised pancreatic cancer tests.

Eligibility criteria

Qualifiers

Males and females

Adult patients ≥ 18 years old

VAPOR 1: patients with either a) Histologically confirmed PDAC*; b) New-onset diabetes mellitus or chronic pancreatitis; or c) Non-specific gastrointestinal symptoms, but a radiologically-normal pancreas

VAPOR Bioresource: patients undergoing pancreatic resection for a) Histologically confirmed PDAC*; or b) Benign pancreatic disorders e.g. intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis

Disqualifiers

Patients who have already received chemotherapy, radiotherapy or surgery for their PDAC

History of another cancer within the previous five years

Previous upper gastrointestinal surgery

Patients who are unable to provide a breath sample

Trial design

Treatments tested in this trial

  • Breath test
  • Collection of matched samples of breath, biofluids and pancreatic tissue

Treatment groups

1,005 Participants
are divided into 5 treatment groups

Sponsors and collaborators

Imperial College London

Lead sponsor

Pancreatic Cancer UK

Collaborator

Imperial College Healthcare NHS Trust

Collaborator

Royal Free Hospital NHS Foundation Trust

Collaborator

Liverpool University Hospitals NHS Foundation Trust

Collaborator

The Leeds Teaching Hospitals NHS Trust

Collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

Collaborator

University Hospital Southampton NHS Foundation Trust

Collaborator

Royal Surrey County Hospital NHS Foundation Trust

Collaborator

University Hospital Birmingham NHS Foundation Trust

Collaborator

Manchester University NHS Foundation Trust

Collaborator

Newcastle-upon-Tyne Hospitals NHS Trust

Collaborator

Swansea Bay University Health Board

Collaborator

Dorset County Hospital NHS Foundation Trust

Collaborator

North Tees and Hartlepool NHS Foundation Trust

Collaborator

University Hospital Plymouth NHS Trust

Collaborator

Barts & The London NHS Trust

Collaborator

Milton Keynes University Hospital NHS Foundation Trust

Collaborator

Buckinghamshire Healthcare NHS Trust

Collaborator

Southern Health

Collaborator